Literature DB >> 3127435

Apocrine nevus.

J H Kim1, H Hur, C W Lee, Y T Kim.   

Abstract

Mesh：

Year:  1988        PMID： 3127435     DOI： 10.1016/s0190-9622(88)80291-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  8 in total

1.  LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer.

Authors:  A Giro-Perafita; L Luo; A Khodadadi-Jamayran; M Thompson; B Akgol Oksuz; A Tsirigos; B D Dynlacht; I Sánchez; F J Esteva
Journal:  NPJ Breast Cancer       Date:  2020-01-06

Review 2.  Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.

Authors:  Giampaolo Bianchini; Carmine De Angelis; Luca Licata; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2021-11-09       Impact factor: 66.675

3.  Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.

Authors:  Rebecca Dent; Mafalda Oliveira; Steven J Isakoff; Seock-Ah Im; Marc Espié; Sibel Blau; Antoinette R Tan; Cristina Saura; Matthew J Wongchenko; Na Xu; Denise Bradley; Sarah-Jayne Reilly; Aruna Mani; Sung-Bae Kim
Journal:  Breast Cancer Res Treat       Date:  2021-07-15       Impact factor: 4.872

4.  Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Authors:  Andrew Tutt; Holly Tovey; Maggie Chon U Cheang; Sarah Kernaghan; Lucy Kilburn; Patrycja Gazinska; Julie Owen; Jacinta Abraham; Sophie Barrett; Peter Barrett-Lee; Robert Brown; Stephen Chan; Mitchell Dowsett; James M Flanagan; Lisa Fox; Anita Grigoriadis; Alexander Gutin; Catherine Harper-Wynne; Matthew Q Hatton; Katherine A Hoadley; Jyoti Parikh; Peter Parker; Charles M Perou; Rebecca Roylance; Vandna Shah; Adam Shaw; Ian E Smith; Kirsten M Timms; Andrew M Wardley; Gregory Wilson; Cheryl Gillett; Jerry S Lanchbury; Alan Ashworth; Nazneen Rahman; Mark Harries; Paul Ellis; Sarah E Pinder; Judith M Bliss
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

5.  The epithelial sodium channel has a role in breast cancer cell proliferation.

Authors:  Adam W Ware; Joshua J Harris; Tania L Slatter; Heather E Cunliffe; Fiona J McDonald
Journal:  Breast Cancer Res Treat       Date:  2021-02-25       Impact factor: 4.872

6.  Genomic features of rapid versus late relapse in triple negative breast cancer.

Authors:  Yiqing Zhang; Sarah Asad; Zachary Weber; David Tallman; William Nock; Meghan Wyse; Jerome F Bey; Kristin L Dean; Elizabeth J Adams; Sinclair Stockard; Jasneet Singh; Eric P Winer; Nancy U Lin; Yi-Zhou Jiang; Ding Ma; Peng Wang; Leming Shi; Wei Huang; Zhi-Ming Shao; Mathew Cherian; Maryam B Lustberg; Bhuvaneswari Ramaswamy; Sagar Sardesai; Jeffrey VanDeusen; Nicole Williams; Robert Wesolowski; Samilia Obeng-Gyasi; Gina M Sizemore; Steven T Sizemore; Claire Verschraegen; Daniel G Stover
Journal:  BMC Cancer       Date:  2021-05-18       Impact factor: 4.430

7.  Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.

Authors:  Thorsten Heilmann; Anna-Lena Rumpf; Marijke Roscher; Maren Tietgen; Olga Will; Mirko Gerle; Timo Damm; Christoph Borzikowsky; Nicolai Maass; Claus-Christian Glüer; Sanjay Tiwari; Anna Trauzold; Christian Schem
Journal:  Arch Gynecol Obstet       Date:  2020-03-14       Impact factor: 2.344

8.  SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells.

Authors:  Nourhan Hassan; Niklas Rutsch; Balázs Győrffy; Nancy Adriana Espinoza-Sánchez; Martin Götte
Journal:  Sci Rep       Date:  2020-02-10       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.